Aptose Shareholders Approve Hanmi Takeover as AML Therapy Shows Promise — Aptose Biosciences Inc.

Event summary

Aptose shareholders approved a C$2.41 per share takeover by Hanmi Pharmaceutical, representing a 28% premium over Aptose’s 30-day VWAP.
Final court approval received for the arrangement, with closing expected by late April 2026.
TUS+VEN+AZA triplet therapy showed 90% clinical response rates and 78% MRD negativity in newly diagnosed AML patients.
Aptose reported a net loss of $25.5 million for 2025, down slightly from $25.4 million in 2024.

The big picture

Aptose’s acquisition by Hanmi marks a strategic shift for the clinical-stage oncology company, providing financial stability amid promising but costly AML therapy development. The deal comes as precision oncology gains traction, with Hanmi likely aiming to leverage Aptose’s mutation-agnostic treatment approach in a competitive hematology market.

What we're watching

Deal Completion: Whether the Hanmi acquisition closes by late April 2026 as planned, contingent on regulatory approvals.
Therapy Efficacy: The pace at which TUS+VEN+AZA triplet therapy data will be presented at EHA2026 and its potential impact on AML treatment standards.
Financial Stability: How Aptose will manage its cash runway, currently at $4.1 million, until the deal closes.